{{Drugbox
| IUPAC_name        = (8S,9S,10R,13S,14S,17S)-17-acetyl-6-chloro-10,13-dimethyl-8,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
| image             = Trengestone.svg
| CAS_number        = 5192-84-7
| ATC_prefix        = None
| ATC_suffix        = 
| PubChem           = 56840930
| DrugBank          = 
| ChemSpiderID      = 16736068
| chemical_formula =
| C=21 | H=25 | Cl=1 | O=2 
| molecular_weight  = 344.875 g/mol
| SMILES = CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)C=C[C@]34C)Cl)C
| synonyms          = Ro 4-8347; 1,6-''bis''dehydro-6-chlororetroprogesterone<ref name="pmid4925556">{{cite journal |vauthors=Andreoli C, Fiorentino F, Lenzi G | title = [Clinical studies and endometrial histomorphological findings by means of a new retroprogesterone derivative: 1,6 bis dehydro-6-chloro-retroprogesterone (Trengestone)] | language = Italian | journal = Minerva Ginecol | volume = 22 | issue = 18 | pages = 874–9 |date=September 1970  | pmid = 4925556 | doi = | url = }}</ref>
| StdInChI          = 1S/C21H25ClO2/c1-12(23)15-4-5-16-14-11-19(22)18-10-13(24)6-8-21(18,3)17(14)7-9-20(15,16)2/h6,8,10-11,14-17H,4-5,7,9H2,1-3H3/t14-,15+,16-,17-,20+,21+/m0/s1
| StdInChIKey       = USXVMPAWZOOYDE-HGUQNLGYSA-N
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      =  <!-- A / B            / C / D / X -->
| pregnancy_category=  
| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Rx-only
| routes_of_administration = [[Oral administration|Oral]]
}}

'''Trengestone''' ([[International Nonproprietary Name|INN]]) (brand names '''Reteroid''', '''Retroid''', '''Retrone'''; former developmental code name '''Ro 4-8347'''), also known as '''6-chloro-6,7-didehydroretroprogesterone''' or '''6-chloro-9β-10α-pregna-1,4,6-triene-3,20-dione''', is a [[steroid]]al [[progestin]] of the [[retroprogesterone]] group<ref name="HorskyPresl2012">{{cite book|author1=J. Horsky|author2=J. Presl|title=Ovarian Function and its Disorders: Diagnosis and Therapy|url=https://books.google.com/books?id=7IrpCAAAQBAJ&pg=PA329|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-8195-9|pages=329–}}</ref> related to [[dydrogesterone]] that was formerly used to treat [[menstrual disorder]]s.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA259|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=259–}}</ref><ref name="Brudon1983">{{cite book|author=Pascale Brudon|title=Médicaments pour tous en l'an 2000?: les multinationales pharmaceutiques suisses face au tiers monde : l'exemple du Mexique|url=https://books.google.com/books?id=ZgLwphUSEN0C&pg=PA93|year=1983|publisher=Editions d'en bas|isbn=978-2-8290-0039-3|pages=93–}}</ref><ref name="MortonMorton1999">{{cite book|author1=Dr. Ian Morton|author2=I.K. Morton|author3=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA279|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=279–}}</ref> It was synthesized in 1964 and was introduced for medical use by [[Hoffmann-La Roche|Roche]] in 1974.<ref name="Elks2014" /><ref name="Brudon1983" /><ref name="MortonMorton1999" />

==References==
{{Reflist|2}}


{{Progestogens and antiprogestogens}}
{{Progesterone receptor modulators}}

[[Category:Diketones]]
[[Category:Organochlorides]]
[[Category:Pregnanes]]
[[Category:Progestogens]]


{{steroid-stub}}
{{genito-urinary-drug-stub}}